Investing

Novo Nordisk : NVO

NVO

Stock Data

$50.66

$1.89 (3.87%)

Asset Type

Common Stock

Exchange

NYSE

Currency

USD

Country

USA

Sector

HEALTHCARE

Industry

DRUG MANUFACTURERS - GENERAL

Novo Nordisk A / S, a healthcare company, is dedicated to the research, development, manufacture and marketing of pharmaceutical products globally. The company is headquartered in Bagsvaerd, Denmark.

All Novo Nordisk Articles

163 Articles

Rich Duprey | Jun 30, 2026 at 9:38 AM EDT

AI Is Transforming Drug Discovery. Here Is the Next Trillion-Dollar Biotech Opportunity

Artificial intelligence is reshaping nearly every industry, but some of its biggest opportunities are emerging far from Silicon Valley. Biotechnology…

Alex Sirois | Jun 23, 2026 at 1:55 PM EDT

Forget Novo Nordisk. Pfizer’s Obesity Pipeline Is Coming, and It Pays You 6.8% While You Wait

Everyone is still arguing about Novo Nordisk (NYSE:NVO | NVO Price Prediction), the Danish obesity juggernaut whose GLP-1 franchise turned…

Joel South | Jun 17, 2026 at 3:20 PM EDT

3 Beaten-Down Stocks That Could Roar Back in June

June is shaping up as a stock-picker’s month. Spring volatility has settled, and contrarian investors are scanning the wreckage for…

Joel South | Jun 13, 2026 at 9:30 AM EDT

3 Ridiculously Cheap Healthcare Stocks to Buy in June

Healthcare has spent 2026 on the sidelines while the rest of the market does the heavy lifting. The Health Care…

Vandita Jadeja | Jun 11, 2026 at 2:58 PM EDT

Eli Lilly vs Novo Nordisk: The Battle for Obesity Drug Supremacy

Eli Lilly (NYSE: LLY | LLY Price Prediction) and Novo Nordisk (NYSE: NVO) reported Q1 2026 results that pulled the…

Jeremy Phillips | Jun 11, 2026 at 9:30 AM EDT

The GLP-1 stock nobody is pricing in isn’t a drugmaker

Scott Galloway and Ed Elson laid out the math on Prof G Markets and it should make every fast food…

Gerelyn Terzo | Jun 3, 2026 at 9:03 AM EDT

Live Nasdaq Composite: Markets Take a Breather amid Stellar AI Earnings Cycle

This article will be updated throughout the day, so check back often for more daily updates.  The markets are cradling…

Jeremy Phillips | Jun 3, 2026 at 8:38 AM EDT

5 Stocks Set to Cash in on The Next 90-Million Customer Industry. (It’s Not AI)

Wells Fargo’s chief agriculture economist Dr. Michael Swanson told Bloomberg Businessweek on May 29 that GLP-1 weight-loss drugs (Ozempic, Wegovy,…

Trey Thoelcke | May 26, 2026 at 8:50 AM EDT

If Viking Therapeutics Is Acquired, Here’s Who Wins

Polymarket traders are watching one biotech more closely than any other for an acquisition. Viking Therapeutics (NASDAQ: VKTX | VKTX…

Vandita Jadeja | May 21, 2026 at 8:25 AM EDT

Can Eli Lilly Stock Reach $1800 by 2030? Here Is the Bull Case

Eli Lilly (NYSE:LLY | LLY Price Prediction) is growing like a software company. Q1 2026 revenue hit $19.80B, up 55.5%…

Alex Sirois | May 18, 2026 at 1:55 PM EDT

Three Biotechs That Are Top Takeover Targets

Eli Lilly (NYSE:LLY | LLY Price Prediction) is the stock everyone wants to talk about, and the reasons are obvious:…

David Moadel | May 5, 2026 at 10:44 AM EDT

Barclays Hikes Eli Lilly Price Target to $1,400: Tirzepatide Momentum Steals the Show

Eli Lilly (NYSE:LLY | LLY Price Prediction) received another bullish call from Wall Street. Barclays analyst Emily Field raised her…

Thomas Richmond | Apr 30, 2026 at 8:05 PM EDT

Fast Money Panel Says Novo Nordisk Now More Compelling Than Eli Lilly After Falling 70%

CNBC’s Fast Money panel recently made a notable pivot on its April 24 episode, arguing that Novo Nordisk (NYSE:NVO |…

David Moadel | Apr 24, 2026 at 12:01 PM EDT

JPMorgan Initiates Hims & Hers With Overweight: Could the Novo Nordisk Deal Be the Turning Point?

Hims & Hers Health (NYSE:HIMS) just picked up a high-profile endorsement. JPMorgan analyst Cory Carpenter initiated coverage with an Overweight…

Ian Cooper | Apr 22, 2026 at 12:24 PM EDT

Biotech Investor Alex Karnal: GLP-1 Drugs Signal ‘Trillion-Dollar Revolution’ in Public Health

Alex Karnal, co-founder and CIO of Braidwell, a life sciences investment firm, spent 20 years building and backing biotech companies…